Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Nous-209 Genetic Vaccine for the Treatment of MSI-H Colorectal, Gastric and Gastro-esophageal junction Tumors
Glossary on
off
Printer Friendly Page Nous-209 Genetic Vaccine for the Treatment of MSI-H Colorectal, Gastric and Gastro-esophageal junction Tumors

Nous-209 Genetic Vaccine for the Treatment of MSI-H Colorectal, Gastric and Gastro-esophageal junction Tumors

Clinicaltrials.gov identifier:
NCT04041310


Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors

Study Contact Information:

Questions about the study can be directed to the study contacts listed below or to Dr. Patricia Delaite at [email protected]

Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors

About the Study

The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers  or . Participants will receive the vaccine in combination with the drug Keytruda (pembrolizumab). NOTE: This study is no longer enrolling people. 

 

This Study is Open To:

NOTE: This study is no longer enrolling people. 

This Study is Not Open To:

NOTE: This study is no longer enrolling people.